3,610
Views
1
CrossRef citations to date
0
Altmetric
Articles

HIV/AIDS treatment funding system to support the people affected by HIV/AIDS in Surakarta, Indonesia

ORCID Icon, &

References

  • Agarwal, S. K., Bagchi, S., & Yadav, R. K. (2017). Hemodialysis patients treated for hepatitis C using a Sofosbuvir-based regimen. Kidney International Reports, 2(5), 831–835.
  • American Nurses Association. (2014). Code of ethics for nurses with interpretive statements. Silver Spring, MD: American Nurses Association.
  • Andorno, R. (2007). Global bioethics at UNESCO: In defense of the universal declaration on bioethics and human rights. Journal of Medical Ethics, 33(3), 150–154.
  • Apanga, S., Punguyire, D., & Adjei, G. (2012). Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: A pilot study. Pan African Medical Journal, 12(1), 1–6.
  • Arjun, B. Y., Unnikrishnan, B., Ramapuram, J. T., Thapar, R., Mithra, P., Kumar, N., … Darshan, B. (2017). Factors influencing quality of life among people living with HIV in coastal South India. Journal of the International Association of Providers of AIDS Care (JIAPAC), 16(3), 247–253.
  • Arts, E. J., & Hazuda D. J. (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine, 2(4), 1–23.
  • Atkins, J. H., Rubenstein, S. L., Sota, T. L., Rueda, S., Fenta, H., Bacon, J., & Rourke, S. B. (2010). Impact of social support on cognitive symptom burden in HIV/AIDS. AIDS Care, 22(7), 793–802.
  • Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., … Becker, M. F. (2000). Human immunodeficiency virus type 1 mutations selected In patients failing Efavirenz combination therapy. Antimicrobial Agents and Chemotherapy, 44(9), 2475–2484.
  • Bemelmans, M., van den Akker, T., Ford, N., Philips, M., Zachariah, R., Harries, A., … Massaquoi, M. (2010). Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Tropical Medicine and International Health, 15(12), 1413–1420.
  • Berenguer, J., Álvarez-Pellicer, J., Martín, P. M., López-Aldeguer, J., Von-Wichmann, M. A., Quereda, C., … González-García, J. (2009). Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology, 50(2), 407–413.
  • Boyer, P. L., Sarafianos, S. G., Arnold, E., & Hughes, S. H. (2001). Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Journal of Virology, 75(10), 4832–4842.
  • Coyne, I. T. (1997). Sampling in qualitative research. Purposeful and theoretical sampling; merging or clear boundaries? Journal of Advanced Nursing, 26(3), 623–630.
  • Creese, A., Floyd, K., Alban, A., & Guinness, L. (2002). Cost-effectiveness of HIV/AIDS interventions in Africa: A systematic review of the evidence. The Lancet, 359, 1635–1642.
  • Creswell, J. W., & Poth, C. N. (2016). Qualitative inquiry and research design: Choosing among five approaches. Singapore: Sage Publications Inc.
  • Ditjen, P. P., & Kemenkes, P. L. (2016). Data statistik HIV di Indonesia 2016, 1–3. Jakarta: Ditjen PP & PL Kemenkes RI.
  • Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., & Mori, J. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activit. Antimicrobial Agents and Chemotherapy, 49(11), 4721–4732.
  • Duncan, H. D. (2017). Communication and social order. New York: Routledge.
  • Dworkin, M., Hanson, D., Kaplan, J., Jones, J., Ward, J., & The Adult and Adolescent Spectrum of HIV disease Project (2000). Risk for preventable opportunistic infections inpersons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. Journal of Infectious Diseases, 182, 611–615.
  • Dykes, C., Fox, K., Lloyd, A., Chiulli, M., Morse, E., & Demeter, L. M. (2001). Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology, 285(2), 193–203.
  • Fatiregun, A. A., Mofolorunsho, K. C., & Osagbemi, K. G. (2009). Quality of life of people living with HIV/AIDS In Kogi State, Nigeria. Benin Journal of Postgraduate Medicine, 11(1), 21–27.
  • Flick, U., von Kardoff, E., & Steinke, I. (2004). A companion to qualitative research. London: Sage Publications Inc.
  • Folasire, O. F., Irabor, A. E., & Folasire, A. M. (2012). Quality of life of people living with HIV and AIDS attending the antiretroviral clinic, University College Hospital, Nigeria. African Journal of Primary Health Care and Family Medicine, 4(1), 1–8.
  • Fuchs, V. R. (1996). Economics, values, and health care reform. American Economic Review, 86(1), 1–24.
  • Galarraga, O., Wirtz, V. J., Figueroa-Lara, A., Santa-Ana-Tellez, Y., Coulibaly, I., & Viisainen, K. (2011). Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics, 29(7), 579–599.
  • Ganesh, S., & Rampersad, R. (2018). Does South Africa need a HIV-AIDS regulatory framework as a public management Tool for HIV-AIDS programmes? Indian Journal of Public Health Research & Development, 9(1), 305–308.
  • Goldie, S. J., Yazdanpanah, Y., Losina, E., Weinstein, M. C., Anglaret, X., Walensky, R. P., … Freedberg, K. A. (2006). Cost-effectiveness of HIV treatment in resource-poor settings-The case of Cote d’Ivoire. New England Journal of Medicine, 355(11), 1141–1153.
  • Greener, R. (2006). AIDS and macroeconomic impact. In S. Forsythe (Ed.), State of the Art: AIDS and economics (pp. 49–55). Washington, DC: Policy Project.
  • Grossman, M. (1972). On the concept of health capital and the demand for health. Journal of Political Economy, 80(2), 223–255.
  • Handayani, R., Herman, M., Mujiati, G., & Masitoh, S. (2017). Accessibility of children living with HIV/AIDS to hospitals in ten districts in Indonesia. Asian Journal of Medicine and Health, 4(4), 1–10.
  • Hendricks, K. M., Erzen, H. D., Wanke, C. A., & Tang, A. M. (2010). Nutrition issues in the HIV-infected injection drug user: Findings from the nutrition for healthy living cohort. Journal of the American College of Nutrition, 29(2), 136–143.
  • Hipolito, R. L., Oliveira, D. C., Costa, T. L. D., Marques, S. C., Pereira, E. R., & Gomes, A. M. T. (2017). Quality of life of people living with HIV/AIDS: Temporal, socio-demographic and perceived health relationship. Revista Latino-Americana de Enfermagem, 20(25), e2874.
  • Hongoro, C., Mturi, A. J., & Kembo, J. (2008). Review of national AIDS councils in Africa: Findings from five countries. SAHARA-J: Journal of Social Aspects of HIV/AIDS, 5(4), 192–200.
  • Iacob, S. A., Iacob, D. G., & Jugulete, G. (2017). Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Frontiers in Pharmacology, 8, 831.
  • Jack, S., & Baxter, P. (2008). Qualitative case study methodology: Study design and implementation for Novice. The Qualitative Report, 13(4), 544–559.
  • Kaiser, J. D., Campa, A. M., Ondercin, J. P., Leoung, G. S., Pless, R. F., & Baum, M. K. (2006). Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: A prospective, double-blinded, placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes, 42(5), 523–528.
  • Kirkcaldy, E. M., Spiegel, P., Abdalla, F., & Erdelmann, F. (2006). The development of programme strategies for integration of HIV, food and nutrition activities in refugee settings. Geneva: UNAIDS Best Practice Collection.
  • Lalezari, J. P., Henry, K., O’Hearn, M., Montaner, J. S., Piliero, P. J., Trottier, B., … Chung, J. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine, 348(22), 2175–2185.
  • Lamontagne, E., Over, M., & Stover, J. (2019). The economic returns of ending the AIDS epidemic as a public health threat. Health Policy, 123(1), 104–108.
  • Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., … Liegler, T. (2016). Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual Health services. JAMA Internal Medicine, 176(1), 75–84.
  • Lodi, S., Phillips, A., Touloumi, G., Geskus, R., Meyer, L., Thiébaut, R., … Porter, K. (2011). Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds 200, 350, and 500 cells/mm3: Assessment of need following changes in treatment guidelines. Clinical Infectious Diseases, 53(8), 817–825.
  • Loutfy, M., Tharao, W., Logie, C., Aden, M. A., Chambers, L. A., Wu, W., … Calzavara, L. (2015). Systematic review of stigma reducing interventions for African/black diasporic women. Journal of the International AIDS Society, 8(18), 19835.
  • Mai, H. T., Le, G. M., Tran, B. X., Do, H. N., Latkin, C. A., Nguyen, L. T., … Ho, C. S. (2018). Adherence to antiretroviral therapy among HIV/ AIDS patients in the context of early treatment initiation in Vietnam. Patient Preference and Adherence, 11(12), 2131–2137.
  • Miles, M. B., Huberman, A. M., & Saldana, J. (2014). Qualitative data analysis: A methods sourcebook. California: Sage Publication Inc.
  • Moon, S., Van Leemput, L., Durier, N., Jambert, E., Dahmane, A., Jie, Y., … Saranchuk, P. (2008). Out-of-pocket costs of AIDS care in China: Are free antiretroviral drugs enough? AIDS Care, 20(8), 984–994.
  • Morse, J. M. (2000). Determining sample size. Qualitative Health Research, 10(1), 3–5.
  • Mshana, G. H., Wamoyi, J., Busza, J., Zaba, B., Changalucha, J., Kaluvya, S., & Urassa, M. (2006). Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early Rural Referrals to the National Program. AIDS Patient Care and STDs, 20(9), 649–657.
  • Naeger, L. K., Margot, N. A., & Miller, M. D. (2002). ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy, 46(7), 2179–2184.
  • Odili, V. U., Ikhurionan, I. B., Usifoh, S. F., & Oparah, A. C. (2011). Determinants of quality of life in HIV/AIDS patients. West African Journal of Pharmacy, 22(1), 42–48.
  • Oguntibeju, O. O. (2012). Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS (Auckland, N.Z.), 4, 117–124.
  • Onah, O. P., Pharm, D., & Pharm, F. P. C. (2016). Affordability of antibiotic therapy of bacterial opportunistic infections in HIV/AIDS. World Journal of Pharmacy and Pharmaceutical Sciences, 5(9), 147–159.
  • Orb, A., Eisenhauer, L., & Wynaden, D. (2001). Ethics in qualitative research. Journal of Nursing Scholarship, 33(1), 93–96.
  • Parslow, R., Jorm, A., Christensen, H., Jacomb, P., & Rodgers, B. (2004). Gender differences in factors affecting use of health services: An analysis of a community study of middle-aged and older Australians. Social Science & Medicine, 59(10), 2121–2129.
  • Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., … Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30.
  • Patton, M. Q. (2002). Qualitative interviewing. Qualitative Research and Evaluation Methods, 3(1), 344–347.
  • Pérez-Molina, J. A., Martínez, E., Blasco, A. J., Arribas, J. R., & Gatell, J. M. (2019). Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiologia Clinica (English ed.), 37(3), 151–115.
  • Phelps, C. E. (2003). Health economics (3rd ed). Boston: Addison Wesley.
  • Rathbun, C. (2017). Antiretroviral therapy for HIV infection, Medscape. Retrieved from: https://emedicine.medscape.com/article/1533218-overview.
  • Razavi, P., Hajifathalian, K., Saeidi, B., Esmaeeli Djavid, G., Rasoulinejad, M., Hajiabdolbaghi, M., … Mohraz, M. (2012). Quality of life among persons with HIV/AIDS in Iran: Internal reliability and validity of an international instrument and associated factors. AIDS Research and Treatment, 2012, 1–6.
  • Riddell, J., Amico, K. R., & Mayer, K. H. (2018). HIV preexposure prophylaxis: A review. The Journal of the American Medical Association, 319(12), 1261–1268.
  • Rigourd, M. L., Ehresmann, C., Parniak, M. A., Ehresmann, B., & Marquet, R. (2002). Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: Comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis. Journal of Biological Chemistry, 277(210), 18611–18618.
  • Rosen, S., Ketlhapile, M., Sanne, I., & DeSilva, M. B. (2007). Cost to patients of obtaining treatment for HIV/AIDS in South Africa. South African Medical Journal, 97(7), 524–529.
  • Sandelowski, M. (1995). Focus on qualitative methods: Sample size in qualitative research. Research in Nursing & Health, 18(2), 179–183.
  • Scambler, G., Higgs, P., & Jones, I. (2002). A critical realist perspective on class relations and health inequalities. Research in the Sociology of Health Care, 20, 57–75.
  • Shaheen, M., Pradhan, S., & Ranajee, G. (2018). Sampling in qualitative research in qualitative techniques for workplace data analysis. In M. Gupta, M. Shaheen, & K. P. Reddy (Eds.), Qualitative techniques for workplace data analysis (pp. 25–51). Hershey, PA: IGI Global.
  • Stake, R. E. (1995). The art of case study research. Thousand Oaks, CA: Sage Publication Inc.
  • Suri, H. (2011). Purposeful sampling in qualitative research synthesis. Qualitative Research Journal, 11(2), 63–75.
  • Tran, B. X., Phan, H. T., Latkin, C. A., Nguyen, H. L. T., Hoang, C. L., Ho, C. S., & Ho, R. (2019). Understanding Global HIV stigma and discrimination: Are contextual factors sufficiently studied? (GAP RESEARCH). International J Journal of Environmental Research and Public Health, 16(1899), 1–19.
  • Tuller, D. M., Bangsberg, D. R., Senkungu, J., Ware, N. C., Emenyonu, N., & Weiser, S. D. (2010). Transportation costs impede sustained adherence and access to HAART in a clinic population in Southwestern Uganda: A qualitative study. AIDS and Behavior, 14(4), 778–784.
  • UNAIDS. (2017). The global HIV/AIDS epidemic-progress and challenges. The Lancet, 390(10092), 333.
  • Vogenberg, F. R. (2001). Introduction to applied pharmacoeconomics. (Vol.120). USA: Mc Graw Hill Companies.
  • Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., … Freedberg, K. A. (2006). The survival benefits of AIDS treatment in the United States. The Journal of Infectious Diseases, 194(1), 11–19.
  • Walker, W. (2007). Ethical considerations in phenomenological research. Nurse Researcher, 14(3), 36–45.
  • WHO. (2015). Guideline on when to Start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO Press.
  • WHO. (2016a). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for Key populations. Geneva: WHO Press.
  • WHO. (2016b). The Global HIV/AIDS epidemic. Geneva: WHO Press.
  • WHO, UNAIDS, & UNICEF. (2008). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report, June 2008. Retrieved from http://www.who.int/hiv/pub/2008progressreport/en/index.html.
  • Yin, R. K. (2017). Case study research and applications: Design and methods (4th ed). Thousand Oaks, CA: Sage Publications Inc.
  • Zweifel, P., Breyer, F., & Kifmann, M. (2009). Health economics. Berlin: Springer.